跳转至内容
Merck
CN

N3376

烟酰胺

≥98% (HPLC), powder, PARP inhibitor

别名:

吡啶-3-甲酰胺, 烟碱酰胺, 烟酰胺, 维生素 B3, 维生素 PP

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C6H6N2O
化学文摘社编号:
分子量:
122.12
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
202-713-4
MDL number:
Beilstein/REAXYS Number:
383619
Assay:
≥98% (HPLC)
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


产品名称

烟酰胺, ≥98% (HPLC), powder

assay

≥98% (HPLC)

form

powder

color

white

mp

128-131 °C (lit.)

application(s)

cell analysis

SMILES string

NC(=O)c1cccnc1

InChI

1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

InChI key

DFPAKSUCGFBDDF-UHFFFAOYSA-N

Gene Information

Application

用作某些酶的辅助因子

Biochem/physiol Actions

烟酰胺是维生素B3的酰胺衍生物,是PARP抑制剂

Features and Benefits

该化合物是基因调控研究推荐产品。点击此处 ,查看更多基因调控精选产品。想要了解有关生物活性小分子在其他研究领域应用的更多信息,请访问 sigma.com/discover-bsm

Preparation Note

本品可在室温和干燥条件下密封保存。


Still not finding the right product?

Explore all of our products under 烟酰胺


pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Eye Irrit. 2

存储类别

11 - Combustible Solids

flash_point_f

302.0 °F - closed cup

flash_point_c

150 °C - closed cup

ppe

dust mask type N95 (US), Eyeshields, Gloves



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


商品

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

Organoid culture products to generate tissue and stem cell derived 3D brain, intestinal, gut, lung and cancer tumor organoid models.

可生成组织和干细胞来源3D脑、胃肠道、肺和癌症肿瘤类器官模型的类器官培养产品。


Christian W Johnson et al.
Cell reports, 28(6), 1538-1550 (2019-08-08)
Ras GTPases are mutated at codons 12, 13, and 61, with different frequencies in KRas, HRas, and NRas and in a cancer-specific manner. The G13D mutant appears in 25% of KRas-driven colorectal cancers, while observed only rarely in HRas or
Robert J Motzer et al.
The Lancet. Oncology, 14(6), 552-562 (2013-04-20)
In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib had a longer progression-free survival (PFS). Here, we report overall survival and updated efficacy, quality
Jordi Bruix et al.
Gut, 63(5), 844-855 (2014-02-18)
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death and is currently the main event leading to death in patients with cirrhosis. Evolving information suggests that the metabolic syndrome with non-alcoholic liver disease may be an important



全球贸易项目编号

货号GTIN
N3376-500G04061834115984
N3376-100G04061834115977
N3376-1KG04061826236772